Enfortumab (Anti-Nectin-4) is a human monoclonal antibody targeting Nectin-4 antigen. Enfortumab has been used for the research of urothelial cancer.
Enfortumab-SAP is a bonded toxin between a biotinylated humanized antibody to Nectin-4 and the secondary conjugate Streptavidin-ZAP containing the ribosome-inactivating protein, saporin.
Enfortumab-SAP eliminates cells expressing Nectin-4. All other cells are left untouched.
The following control is included for validating the specificity of the beta conjugate: BIgG-SAP Human (Cat. #IT-77)
This product is being offered as part of our Beta Testing program. It has saporin activity confirmed, peptide sequences published/confirmed, and/or antibody binding specificity published/confirmed. It has not been characterized or reported in scientific literature. The researcher who first publishes data* will receive a $500 credit for use on ATS products.
*Data subject to review by the scientific team at ATS. See complete details here.
keywords: enfortumab, nectin, nectin-4, anti-nectin-4, urothelial cancer, immunotoxin, streptavidin, saporin